Press release LUME-Ovar 1 December 2009

Boehringer Ingelheim

Boehringer Ingelheim initiates first Phase III clinical trial in Ovarian Cancer

Boehringer Ingelheim broadens clinical trial programme for its investigational cancer compound BIBF 1120*. Patient enrolment completed for phase III study in lung cancer with further frontrunner investigational compound BIBW 2992*.

Ingelheim, Germany, 17 December 2009

Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120*, a novel oral anti-angiogenic agent [1], for its efficacy and safety as first-line treatment in combination with standard chemotherapy compared to placebo in combination with standard chemotherapy in patients with advanced ovarian cancer.
--------------------------------------------------------------------------------
[1]An anti-angiogenic agent inhibits angiogenesis, the process of formation of vessels toward the tumour. The vessel supplies the tumour with oxygen and nutrients to enable its further growth, a pre-requisite for the tumour to spread.

*BIBF 1120 and BIBW 2992 are investigational compounds. Their safety and efficacy have not yet been fully established.

Source for healthcare professionals: www.inoncology.com
* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.

Boehringer Ingelheim on